Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
1.81% $27.51
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 643.89 mill |
EPS: | -5.42 |
P/E: | -5.08 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 96.11 mill |
Avg Daily Volume: | 1.584 mill |
RATING 2024-03-28 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -5.08 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.86x |
Company: PE -5.08 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-4.94 (-117.95%) $-32.45 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 25.53 - 29.49 ( +/- 7.18%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Sepp-lorenzino Laura | Buy | 37 966 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 54 794 | Stock Option (right to buy) |
2024-03-01 | Basta James | Buy | 32 394 | Common Stock |
2024-03-04 | Basta James | Sell | 2 297 | Common Stock |
2024-03-01 | Basta James | Buy | 46 752 | Stock Option (right to buy) |
INSIDER POWER |
---|
85.54 |
Last 100 transactions |
Buy: 1 569 411 | Sell: 123 854 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $27.51 (1.81% ) |
Volume | 1.043 mill |
Avg. Vol. | 1.584 mill |
% of Avg. Vol | 65.82 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:36 | sell | $27.60 | N/A | Active |
---|
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.